If you’re a founder looking to grow your startup, chances are you’re wrestling with more than just product or capital. Talent, scale, and smart execution are the real battlegrounds. That’s exactly what TechCrunch All Stage 2025 is built to address on July 15 at Boston’s SoWa Power Station. Rob Biederman, managing partner at Asymmetric Capital […]
Read more A federal proposal that would ban states and local governments from regulating AI for 10 years could soon be signed into law, as Sen. Ted Cruz (R-TX) and other lawmakers work to secure its inclusion into a GOP megabill ahead of a key July 4 deadline. Here’s what’s at stake.
Read more As warnings mount about AI’s potential to displace millions of jobs, Anthropic on Friday launched a its Economic Futures Program, new initiative to support research and policy development that addresses AI’s economic impacts.
Read more The app is Google’s attempt to compete with ByteDance’s popular CapCut editor.
Read more The firm was founded in 2015 by Jesse Draper. The fund will focus on the physical and financial health of households.
Read more This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology.
This battery recycling company is now cleaning up AI data centers
In a sandy industrial lot outside Reno, Nevada, rows of battery packs that once propelled electric vehicles are now powering a small AI data center.
Redwood Materials, one of the US’s largest battery recycling companies, showed off this array of energy storage modules, sitting on cinder blocks and wrapped in waterproof plastic, during a press tour at its headquarters on June 26.
The event marked the launch of the company’s new business line, Redwood Energy, which will initially repurpose (rather than recycle) batteries with years of remaining life to create renewable-powered microgrids. Such small-scale energy systems can operate on or off the larger electricity grid, providing electricity for businesses or communities. Read the full story.
—James Temple
We’re learning more about what weight-loss drugs do to the body
Weight-loss drugs are this decade’s blockbuster medicines. Drugs like Ozempic, Wegovy, and Mounjaro help people with diabetes get their blood sugar under control and help overweight and obese people reach a healthier weight. And they’re fast becoming a trendy must-have for celebrities and other figure-conscious individuals looking to trim down.
They became so hugely popular so quickly that not long after their approval for weight loss, we saw global shortages of the drugs. Prescriptions have soared over the last five years, but even people who don’t have prescriptions are seeking these drugs out online.
We know they can suppress appetite, lower blood sugar, and lead to dramatic weight loss. We also know that they come with side effects, which can include nausea, diarrhea, and vomiting. But we are still learning about some of their other effects. Read the full story.
—Jessica Hamzelou
This article first appeared in The Checkup, MIT Technology Review’s weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, sign up here.
The must-reads
I’ve combed the internet to find you today’s most fun/important/scary/fascinating stories about technology.
1 The Supreme Court has paved the way to defund Planned Parenthood
By allowing South Carolina to block the organization from its Medicaid program. (WP $)
+ Other red states are likely to follow suit. (CNN)
+ Planned Parenthood may be able to challenge the ban under state law. (Politico)
2 Iran is back online
The country appeared to cut connectivity in a bid to thwart foreign attacks. (Economist $)
3 ICE is using a new facial recognition app
It’s capable of recognizing someone from their fingerprints, too. (404 Media)
+ How a new type of AI is helping police skirt facial recognition bans. (MIT Technology Review)
4 Denmark has a potential solution for malicious deepfakes
By giving its residents copyright to their own body, facial features, and voice. (The Guardian)
+ An AI startup made a hyperrealistic deepfake of me that’s so good it’s scary. (MIT Technology Review)
5 Impossible Foods wants to bring its plant-based burgers to Europe 
After sales started falling in America. (Bloomberg $)
+ Sales of regular old meat are booming in the States. (Vox)
6 The Three Mile Island nuclear plant’s restart is being fast tracked
It’s currently scheduled to start operating a year earlier than anticipated. (Reuters)
+ But bringing the reactor back online is no easy task. (The Register)
+ Why Microsoft made a deal to help restart Three Mile Island. (MIT Technology Review)
7 AI may be making research too easy
New research suggests that using LLMs results in weaker grasps of topics. (WSJ $)
+ It could also be making our thoughts less original. (New Yorker $)
8 Climate tech companies are struggling to weather Trump’s cuts
A lot of startups are expected to fold as a result. (Insider $)
+ The Trump administration has shut down more than 100 climate studies. (MIT Technology Review)
9 Billions of Facebook and Google passwords have been leaked
And people in developing nations are most at risk. (Rest of World)
10 Inside a couples retreat with humans and their AI companions
Chaos ensured. (Wired $)
+ The AI relationship revolution is already here. (MIT Technology Review)
Quote of the day
“[The internet blackout] makes us invisible. And still, we’re here. Still trying to connect with the free world.”
—’Amir,’ a student in Iran, tells the Guardian why young Iranians are working to overcome the country’s internet shutdowns.
One more thing
Maybe you will be able to live past 122
How long can humans live? This is a good time to ask the question. The longevity scene is having a moment, thanks to a combination of scientific advances, public interest, and an unprecedented level of investment. A few key areas of research suggest that we might be able to push human life spans further, and potentially reverse at least some signs of aging.
Researchers can’t even agree on what the exact mechanisms of aging are and which they should be targeting. Debates continue to rage over how long it’s possible for humans to live—and whether there is a limit at all.
But it looks likely that something will be developed in the coming decades that will help us live longer, in better health. Read the full story.
—Jessica Hamzelou
We can still have nice things
A place for comfort, fun and distraction to brighten up your day. (Got any ideas? Drop me a line or skeet ’em at me.)
+ This ancient amphibian skull is pretty remarkable.
+ A new Phantom of the Opera spin-off is coming—but no one really knows what it is.
+ Stop panicking, it turns out Marge Simpson isn’t dead after all.
+ I love these owls in towels 
Weight-loss drugs are this decade’s blockbuster medicines. Drugs like Ozempic, Wegovy, and Mounjaro help people with diabetes get their blood sugar under control and help overweight and obese people reach a healthier weight. And they’re fast becoming a trendy must-have for celebrities and other figure-conscious individuals looking to trim down.
They became so hugely popular so quickly that not long after their approval for weight loss, we saw global shortages of the drugs. Prescriptions have soared over the last five years, but even people who don’t have prescriptions are seeking these drugs out online. A 2024 health tracking poll by KFF found that around 1 in 8 US adults said they had taken one.
We know they can suppress appetite, lower blood sugar, and lead to dramatic weight loss. We also know that they come with side effects, which can include nausea, diarrhea, and vomiting. But we are still learning about some of their other effects.
On the one hand, these seemingly miraculous drugs appear to improve health in other ways, helping to protect against heart failure, kidney disease, and potentially even substance-use disorders, neurodegenerative diseases, and cancer.
But on the other, they appear to be harmful to some people. Their use has been linked to serious conditions, pregnancy complications, and even some deaths. This week let’s take a look at what weight-loss drugs can do.
Ozempic, Wegovy, and other similar drugs are known as GLP-1 agonists; they mimic a chemical made in the intestine, GLP-1, that increases insulin and lowers blood levels of glucose. Originally developed to treat diabetes, they are now known to be phenomenal at suppressing appetite. One key trial, published in 2015, found that over the course of around a year, people who took one particular drug lost between around 4.7% and 6% of their body weight, depending on the dose they took.
Newer versions of that drug were shown to have even bigger effects. A 2021 trial of semaglutide—the active ingredient in both Ozempic and Wegovy—found that people who took it for 68 weeks lost around 15% of their body weight—equivalent to around 15 kilograms.
But there appear to be other benefits, too. In 2024, an enormous study that included 17,604 people in 41 countries found that semaglutide appeared to reduce heart failure in people who were overweight or obese and had cardiovascular disease. That same year, the US approved Wegovy to “reduce the risk of cardiovascular death, heart attack, and stroke in [overweight] adults with cardiovascular disease.” This year, Ozempic was approved to reduce the risk of kidney disease.
And it doesn’t end there. The many users of GLP-1 agonists have been reporting some unexpected positive side effects. Not only are they less interested in food, but they are less interested in alcohol, tobacco, opioids, and other addictive substances.
Research suggests they might protect men from prostate cancer. They might help treat osteoarthritis. Some scientists think the drugs could be used to treat a range of pain conditions, and potentially help people with migraine. And some even seem to protect brain cells from damage in lab studies, and they are being explored as potential treatments for neurological disorders like Alzheimer’s and Parkinson’s (although we don’t yet have any evidence they can be useful here).
The more we learn about GLP-1 agonists, the more miraculous they seem to be. What can’t they do?! you might wonder. Unfortunately, like any drug, GLP-1 agonists carry safety warnings. They can often cause nausea, vomiting, and diarrhea ,and their use has also been linked to inflammation of the pancreas—a condition that can be fatal. They increase the risk of gall bladder disease.
There are other concerns. Weight-loss drugs can help people trim down on fat, but lean muscle can make up around 10% of the body weight lost by people taking them. That muscle is important, especially as we get older. Muscle loss can affect strength and mobility, and it also can also leave people more vulnerable to falls, which are the second leading cause of unintentional injury deaths worldwide, according to the World Health Organization.
And, as with most drugs, we don’t fully understand the effects weight-loss drugs might have in pregnancy. That’s important; even though the drugs are not recommended during pregnancy, health agencies point out that some people who take these drugs might be more likely to get pregnant, perhaps because they interfere with the effects of contraceptive drugs.
And we don’t really know how they might affect the development of a fetus, if at all. A study published in January found that people who took the drugs either before or during pregnancy didn’t seem to face increased risk of birth defects. But other research due to be presented at a conference in the coming days found that such individuals were more likely to experience obstetrical complications and preeclampsia.
So yes, while the drugs are incredibly helpful for many people, they are not for everyone. It might be fashionable to be thin, but it’s not necessarily healthy. No drug comes without risks. Even one that 1 in 8 American adults have taken.
This article first appeared in The Checkup, MIT Technology Review’s weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, sign up here.
In a sandy industrial lot outside Reno, Nevada, rows of battery packs that once propelled electric vehicles are now powering a small AI data center.
Redwood Materials, one of the US’s largest battery recycling companies, showed off this array of energy storage modules, sitting on cinder blocks and wrapped in waterproof plastic, during a press tour at its headquarters on June 26.
The event marked the launch of the company’s new business line, Redwood Energy, which will initially repurpose (rather than recycle) batteries with years of remaining life to create renewable-powered microgrids. Such small-scale energy systems can operate on or off the larger electricity grid, providing electricity for businesses or communities.
Redwood Materials says many of the batteries it takes in for processing retain more than half their capacity.
“We can extract a lot more value from that material by using it as an energy storage project before recycling it,” JB Straubel, Redwood’s founder and chief executive, said at the event.
This first microgrid, housed at the company’s facility in the Tahoe Reno Industrial Center, is powered by solar panels and capable of generating 64 megawatt-hours of electricity, making it one of the nation’s largest such systems. That power flows to Crusoe, a cryptocurrency miner that pivoted into developing AI data centers, which has built a facility with 2,000 graphics processing units adjacent to the lot of repurposed EV batteries.
(That’s tiny as modern data centers go: Crusoe is developing a $500 billion AI data center for OpenAI and others in Abilene, Texas, where it expects to install 100,000 GPUs across its first two facilities by the end of the year, according to Forbes.)
Redwood’s project underscores a growing interest in powering data centers partially or entirely outside the electric grid. Not only would such microgrids be quicker to build than conventional power plants, but consumer ratepayers wouldn’t be on the hook for the cost of new grid-connected power plants developed to serve AI data centers.
Since Redwood’s batteries are used, and have already been removed from vehicles, the company says its microgrids should also be substantially cheaper than ones assembled from new batteries.
COURTESY REDWOOD MATERIALS
Redwood Energy’s microgrids could generate electricity for any kind of operation. But the company stresses they’re an ideal fit for addressing the growing energy needs and climate emissions of data centers. The energy consumption of such facilities could double by 2030, mainly due to the ravenous appetite of AI, according to an April report by the International Energy Agency.
“Storage is this perfectly positioned technology, especially low-cost storage, to attack each of those problems,” Straubel says.
The Tahoe Reno Industrial Center is the epicenter of a data center development boom in northern Nevada that has sparked growing concerns about climate emissions and excessive demand for energy and water, as MIT Technology Review recently reported.
Straubel says the litany of data centers emerging around it “would be logical targets” for its new business line, but adds there are growth opportunities across the expanding data center clusters in Texas, Virginia, and the Midwest as well.
“We’re talking to a broad cross section of those companies,” he says.
Crusoe, which also provides cloud services, recently announced a joint venture with the investment firm Engine No. 1 to provide “powered data center real estate solutions” to AI companies by constructing 4.5 gigawatts of new natural-gas plants.
Redwood’s microgrid should provide more than 99% of the electricity Crusoe’s local facilities need. In the event of extended periods with little sunlight, a rarity in the Nevada desert, the company could still draw from the standard power grid.
Cully Cavness, cofounder and operating chief of Crusoe, says the company is already processing AI queries and producing conclusions for its customers at the Nevada facility. (Its larger data centers are dedicated to the more computationally intensive process of training AI models.)
Redwood’s new business division offers a test case for a strategy laid out in a paper late last year, which highlighted the potential for solar-powered microgrids to supply the energy that AI data centers need.
The authors of that paper found that microgrids could be built much faster than natural-gas plants and would generally be only a little more expensive as an energy source for data centers, so long as the facilities could occasionally rely on natural-gas generators to get them through extended periods of low sunlight.
If solar-powered microgrids were used to power 30 gigawatts of new AI data centers, with just 10% backup from natural gas, it would eliminate 400 million tons of carbon dioxide emissions relative to running the centers entirely on natural gas, the study found.
“Having a data center running off solar and storage is more or less what we were advocating for in our paper,” says Zeke Hausfather, climate lead at the payments company Stripe and a coauthor of the paper. He hopes that Redwood’s new microgrid will establish that “these sorts of systems work in the real world” and encourage other data center developers to look for similar solutions.
Redwood Materials says electric vehicles are its fastest-growing source of used batteries, and it estimates that more than 100,000 EVs will come off US roads this year.
The company says it tests each battery to determine whether it can be reused. Those that qualify will be integrated into its modular storage systems, which can then store up energy from wind and solar installations or connect to the grid. As those batteries reach the end of their life, they’ll be swapped out of the microgrids and moved into the company’s recycling process.
Redwood says it already has enough reusable batteries to build a gigawatt-hour’s worth of microgrids, capable of powering a little more than a million homes for an hour. In addition, the company’s new division has begun designing microgrids that are 10 times larger than the one it unveiled this week.
Straubel expects Redwood Energy to become a major business line, conceivably surpassing the company’s core recycling operation someday.
“We’re confident this is the lowest-cost solution out there,” he says.
Meta’s support for U.S. President Donald Trump may pay off as its pushes back against regional taxes.
The report looks at the value Snap can provide for electronics marketers.